Acadia Pharmaceuticals Inc [NASDAQ: ACAD] closed the trading session at $19.77.
The stocks have a year to date performance of 7.74 percent and weekly performance of 3.35 percent. The stock has been moved at 25.68 percent over the last six months. The stock has performed 16.98 percent around the most recent 30 days and changed 8.21 percent over the most recent 3-months.
If compared to the average trading volume of 2.42M shares, ACAD reached to a volume of 3147704 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Acadia Pharmaceuticals Inc [ACAD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ACAD shares is $24.80 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ACAD stock is a recommendation set at 1.95. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Deutsche Bank have made an estimate for Acadia Pharmaceuticals Inc shares, keeping their opinion on the stock as Hold, with their previous recommendation back on February 11, 2025. While these analysts kept the previous recommendation, Guggenheim dropped their target price from $23 to $20. The new note on the price target was released on January 03, 2025, representing the official price target for Acadia Pharmaceuticals Inc stock. On August 07, 2024, analysts decreased their price target for ACAD shares from 28 to 20.
The Average True Range (ATR) for Acadia Pharmaceuticals Inc is set at 0.73, with the Price to Sales ratio for ACAD stock in the period of the last 12 months amounting to 3.54. The Price to Book ratio for the last quarter was 5.70, with the Price to Cash per share for the same quarter was set at 3.40. Price to Free Cash Flow for ACAD in the course of the last twelve months was 16.23 with Quick ratio for the last quarter at 2.11.
ACAD stock trade performance evaluation
Acadia Pharmaceuticals Inc [ACAD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.35. With this latest performance, ACAD shares gained by 16.98% in over the last four-week period, additionally plugging by 25.68% over the last 6 months – not to mention a drop of -26.12% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACAD stock in for the last two-week period is set at 62.13, with the RSI for the last a single of trading hit 64.91, and the three-weeks RSI is set at 60.36 for Acadia Pharmaceuticals Inc [ACAD]. The present Moving Average for the last 50 days of trading for this stock 17.87, while it was recorded at 18.96 for the last single week of trading, and 16.50 for the last 200 days.
Acadia Pharmaceuticals Inc [ACAD]: An insightful look at the core fundamentals
Acadia Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.11 and a Current Ratio set at 2.29.
Acadia Pharmaceuticals Inc [ACAD]: Institutional Ownership
The top three institutional holders of ACAD stocks are: BAKER BROS. ADVISORS LP with ownership of 42.88 million shares, which is approximately 26.0185%. VANGUARD GROUP INC, holding 13.71 million shares of the stock with an approximate value of $$222.82 million in ACAD stocks shares; and VANGUARD GROUP INC, currently with $$222.75 million in ACAD stock with ownership which is approximately 8.3178%.
